Over the last decade, adjuvant chemotherapy has undergone a significant improvement, Philip says. The field has seen evolution from single-agent gemcitabine to gemcitabine plus capecitabine to FOLFRINOX. Most recently, the PRODIGE 24/CCTG PA.6 trial study demonstrated a significant improvement in survival for patients with resectable pancreatic cancer treated with modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine. Read more . . .
Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the use of FOLFIRINOX in patients with locally advanced pancreatic cancer.